top of page

Fulcrum Therapeutics’ CEO discusses the clinical hold lift of the company’s SCD program.

Alex Sapir explains a tweak in the clinical trial population that allowed the trial to resume.



Comentarios


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page